Taysha Gene Therapies to Participate in Upcoming July Investor Healthcare Conference

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) announced its participation in the William Blair Biotech Focus Conference 2021. The event is scheduled for July 15, 2021, at 11:00 am ET, featuring a fireside chat format. Key executives, including RA Session II (President and CEO), Dr. Suyash Prasad (Chief Medical Officer), and Kamran Alam (Chief Financial Officer), will participate. A live webcast will be accessible via Taysha's website, with an archived version available for 60 days. Taysha focuses on developing gene therapies for central nervous system diseases.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in a virtual fireside chat for the William Blair Biotech Focus Conference 2021.

Conference's Details:
Event:	William Blair Biotech Focus Conference 2021
Date:	Thursday, July 15, 2021
Time:	11:00 am ET
Format:	Fireside chat
Participants:	RA Session II, President, Founder and CEO
	Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
	Kamran Alam, Chief Financial Officer

A live webcast of this conference will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. An archived version of the webcast will be available on the website for 60 days.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005154/en/

FAQ

What is the date and time of Taysha's participation in the William Blair Biotech Focus Conference 2021?

Taysha Gene Therapies will participate in the William Blair Biotech Focus Conference 2021 on July 15, 2021, at 11:00 am ET.

Who are the key executives participating in Taysha's fireside chat?

The fireside chat will feature RA Session II (President and CEO), Dr. Suyash Prasad (Chief Medical Officer), and Kamran Alam (Chief Financial Officer).

How can I access the live webcast of Taysha's conference participation?

The live webcast will be available in the 'Events & Media' section of Taysha's corporate website.

Will there be an archived version of Taysha's conference webcast?

Yes, an archived version of the webcast will be available for 60 days after the event.

What is Taysha Gene Therapies focused on developing?

Taysha Gene Therapies focuses on developing AAV-based gene therapies for treating monogenic diseases of the central nervous system.